Bharat Biotech gets a nod from the Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials of its coronavirus vaccine candidate, Covaxin. Bharat Biotech is developing the vaccine in collaboration with the Indian Council of Medical Research (ICMR).
The Hyderabad-based vaccine maker in its application said that the study would cover 28,500 subjects of age 18 years and above and would be conducted in 19 sites - including Delhi, Mumbai, Patna, and Lucknow - across 10 states.
Latest Videos
